Semaglutide (Ozempic) May Slow Kidney Disease in Type 2 Diabetes: FLOW Trial Results
- Type 2 diabetes occurs when the body fails to appropriately respond to insulin, the hormone that helps regulate blood sugar levels.
- People who have type 2 diabetes are more likely to get chronic kidney disease.
- Semaglutide, also known as Ozempic, is a medication that helps control blood sugar levels when used in conjunction with a healthy diet and regular exercise.
- Recent studies have found that semaglutide helps slow the worsening of kidney disease.
Chronic kidney disease is a problem for one out of every three adults with diabetes. Both type 1 and type 2 diabetes can lead to this kidney issue if blood sugar isn't kept in check.
The problem is that high blood sugar can damage the blood vessels and nephrons, causing them to function poorly.
Since early kidney disease often doesn't show signs, it's super important for people with diabetes to keep an eye on their blood sugar, blood pressure, and cholesterol. Regular doctor visits are key, too.
Semaglutide, also known as Ozempic, belongs to a class of medications called GLP-1 receptor agonists. They act like a natural hormone that boosts insulin production, helps control hunger, and makes you feel full.
The authorities have given the thumbs up for Ozempic to be used along with diet and exercise for treating type 2 diabetes.
But that's not all, it might also help lower the risk of severe heart issues like heart attacks or strokes in people with type 2 diabetes and heart disease. Some research suggests that it may also reduce inflammation in the body, which could be why it offers these additional health benefits.
There's growing evidence that this type of medicine can help reduce inflammation and protect the kidneys from damage, which could slow the progression of kidney disease.
Headline Results Show Reduction In Kidney Disease Cases
Novo Nordisk, the company that makes Ozempic, has shared exciting news from its latest study. They found that semaglutide could lower the chance of kidney disease getting worse by 24% in people with type 2 diabetes and chronic kidney disease.
The full details of the FLOW trial, a study, will be shared at a science conference later in the year. The results have yet to be published in a scientific journal.
FLOW Trial Key Findings:
-
3,533 participants with type 2 diabetes and chronic kidney disease
-
24% reduction in kidney disease progression or death from kidney/heart issues
-
Study ended early due to clear benefit
-
Pending peer-reviewed publication (as of 2024)
A leading researcher from the Steno Diabetes Centre in Copenhagen, Denmark, who worked on the trial, discussed the significance of this finding. With over 500 million people worldwide having diabetes and 30-40% of them also facing chronic kidney disease, finding ways to slow down kidney disease and lessen heart disease risk in these patients is critical.
Another expert, who wasn't part of the study, highlighted the importance of these findings. People with type 2 diabetes and chronic kidney disease are at a higher risk of heart problems and kidney failure, so having treatments that can reduce these risks is essential.
The Ozempic Trial Stopped Early As It Reached Endpoint
In the FLOW trial, researchers examined 3,533 individuals from 28 different countries who had both type 2 diabetes and chronic kidney disease. These participants were picked from 418 places around the world.
The study participants were randomly assigned to receive either semaglutide or a placebo. They took their medicine by taking a weekly shot under the skin, which looked the same whether it was semaglutide or a placebo.
Those taking semaglutide started with a small dose and gradually increased it over time.
Besides this, everyone in the study was also given a type of medicine that helps with high blood pressure and can prevent heart attacks, heart failure, strokes, and kidney problems from getting worse, as long as it was safe and okay for them to take it.
The average age of the participants in the study was approximately 67; most were men, and many were Caucasian. They all had been living with type 2 diabetes for around 17 years on average and also had chronic kidney disease.
The study was initially scheduled to continue until 2024, but it ended early due to the precise results already being evident. The main goal was to see if semaglutide could slow down the progression of kidney disease and prevent deaths from heart and kidney problems. The fact that it could achieve this by 24% is a significant development and could benefit patients.
Ozempic Could Protect Kidney Health, Lowering Cardiac Death Risk
Novo Nordisk announced that their study showed semaglutide could help by reducing the worsening of kidney disease and the risk of dying from heart or kidney problems by 24%, compared to a fake treatment.
However, a New Mexico State University public health expert who wasn't part of the study warned that these are still early findings. He mentioned that more tests are needed with different groups of people worldwide to see if the medicine works as well outside of the lab. This is because people live differently and may have other health issues as well.
Another expert agreed, pointing out that this is the first study to focus specifically on kidney outcomes with this type of medicine in people with type 2 diabetes and chronic kidney disease. The initial results look good, but everyone is waiting for the full details of the study to be shared to understand how effective and safe the treatment is.
Ozempic Is Not Without Side Effects
Ozempic is known to help control blood sugar and might even lower the risk of worsening kidney problems. But, like all medications, it comes with possible side effects.
Common Side Effects of Semaglutide (Ozempic)
-
Nausea or vomiting
-
Constipation or diarrhoea
-
Burping or bloating
-
Stomach pain
-
Fatigue or tiredness
-
Altered taste
Rare but Serious Side Effects
-
Pancreatitis
-
Diabetic retinopathy complications
-
Gallbladder issues (gallstones, inflammation)
-
Kidney injury (rare)
-
Risk of thyroid C-cell tumours (black box warning)
Can Ozempic Change The Treatment Landscape?
A specialist in diabetes care from Texas Diabetes and Endocrinology, who wasn't part of this research, shared some positive thoughts about the study's results. They mentioned that this type of medicine could be a big help if the findings hold up. It could do more than manage blood sugar and weight—it might also tackle one of the serious problems caused by diabetes not being under control, which is chronic kidney disease. This is encouraging news for people with type 2 diabetes.
Other experts also believe that this discovery could be a significant leap forward in finding effective treatments for kidney disease in individuals with type 2 diabetes.
One expert explained that the findings from the FLOW study could change how we take care of people with type 2 diabetes and chronic kidney disease. Now, there is a treatment that can lower the risk of heart and kidney problems while still managing blood sugar levels, even when kidney function isn't optimal.
Another expert agreed, pointing out that since these medicines have several benefits, help keep blood sugar under control, and are generally okay for people with kidney issues, they could transform how we treat people with type 2 diabetes who also have kidney problems. This is a common issue for many people living with type 2 diabetes.
